A Randomised, Controlled Comparison of Vitamin D Strategies is Acute Hip Fracture Patients
Launched by MCMASTER UNIVERSITY · Jan 17, 2007
Trial Information
Current as of September 23, 2025
Completed
Keywords
ClinConnect Summary
Low Vitamin D levels can cause faster bone loss and increase the risk of having a fracture. Patients who experience a hip fracture have low levels of Vitamin D. It is not clear how much Vitamin D must be taken in order to reach this optimal level.
Serum 25-hydroxyvitamin D3 (25-OHD) concentrations are the recognized functional status indicator for vitamin D. Although there is no clear consensus, vitamin D 'insufficiency' has been considered in the range of 25- 75/80 nmol/L. Patients with acute hip fracture are at high risk for a recurrent hip fracture or other fragility fractures (and fall...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fragility hip fracture patient
- • Previous Vitamin D supplementation is okay.
- Exclusion Criteria:
- • Patients with pathological fracture secondary to malignancy or intrinsic bone disease (eg. Paget's disease)
- • Cancer in the past 10 years likely to metastasize to bone
- • Renal insufficiency (creatinine \<30 mls/min)
- • Hypercalcemia (primary hyperparathyroidism; granulomatous diseases; drug-induced such as lithium, thiazides), hypocalcemia, hypercalciuria, fracture or stroke within the last 3 months
- • Hormone replacement therapy, calcitonin, fluoride, or bisphosphonates during the previous 24 months
- • Pre-existing bone abnormality
- • Renal stones in past 10 years
About Mcmaster University
McMaster University, a leading research institution located in Hamilton, Ontario, Canada, is renowned for its innovative approach to education and its commitment to advancing healthcare through rigorous clinical research. The university's diverse research programs are supported by a multidisciplinary team of experts dedicated to improving patient outcomes and public health. With a strong emphasis on evidence-based medicine, McMaster University actively engages in clinical trials that explore new therapies, interventions, and health technologies, fostering collaboration among researchers, healthcare professionals, and industry partners to translate findings into real-world applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Alexandra Papaioannou, M.D., M.Sc.
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials